WO2004032622A8 - Production of peptides in plants as viral coat protein fusions - Google Patents

Production of peptides in plants as viral coat protein fusions

Info

Publication number
WO2004032622A8
WO2004032622A8 PCT/US2003/027563 US0327563W WO2004032622A8 WO 2004032622 A8 WO2004032622 A8 WO 2004032622A8 US 0327563 W US0327563 W US 0327563W WO 2004032622 A8 WO2004032622 A8 WO 2004032622A8
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
plants
production
virus
coat protein
Prior art date
Application number
PCT/US2003/027563
Other languages
French (fr)
Other versions
WO2004032622A2 (en
WO2004032622A3 (en
Inventor
Kenneth E Palmer
Rachel L Toth
Michael Jones
Sean Chapman
Lisa Smolenska
Alison Mccormick
Gregory Pogue
Long Nguyen
Original Assignee
Large Scale Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/457,082 external-priority patent/US20040033585A1/en
Application filed by Large Scale Biology Corp filed Critical Large Scale Biology Corp
Priority to EP03808079A priority Critical patent/EP1549140A4/en
Priority to AU2003296902A priority patent/AU2003296902A1/en
Priority to CA002497798A priority patent/CA2497798A1/en
Publication of WO2004032622A2 publication Critical patent/WO2004032622A2/en
Publication of WO2004032622A3 publication Critical patent/WO2004032622A3/en
Publication of WO2004032622A8 publication Critical patent/WO2004032622A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/12011—Bunyaviridae
    • C12N2760/12211—Phlebovirus, e.g. Rift Valley fever virus
    • C12N2760/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Vaccines and diagnostic composition are made and used for preventing, treating and detecting antigens from a papilloma virus, ebola virus, HIV virus, Rift Valley Fever virus or a parvovirus. The epitopes of these viruses are produced as genetically engineered fusion peptides in plants by infection with a recombinant tobamovirus vectors to express fusion proteins containing the epitope peptides.
PCT/US2003/027563 2002-09-03 2003-09-03 Production of peptides in plants as viral coat protein fusions WO2004032622A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP03808079A EP1549140A4 (en) 2002-09-03 2003-09-03 Production of peptides in plants as viral coat protein fusions
AU2003296902A AU2003296902A1 (en) 2002-09-03 2003-09-03 Production of peptides in plants as viral coat protein fusions
CA002497798A CA2497798A1 (en) 2002-09-03 2003-09-03 Production of peptides in plants as viral coat protein fusions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40779502P 2002-09-03 2002-09-03
US60/407,795 2002-09-03
US10/457,082 2003-06-06
US10/457,082 US20040033585A1 (en) 2002-06-07 2003-06-06 Flexible vaccine assembly and vaccine delivery platform

Publications (3)

Publication Number Publication Date
WO2004032622A2 WO2004032622A2 (en) 2004-04-22
WO2004032622A3 WO2004032622A3 (en) 2005-04-28
WO2004032622A8 true WO2004032622A8 (en) 2007-11-01

Family

ID=32096072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/027563 WO2004032622A2 (en) 2002-09-03 2003-09-03 Production of peptides in plants as viral coat protein fusions

Country Status (4)

Country Link
EP (1) EP1549140A4 (en)
AU (1) AU2003296902A1 (en)
CA (1) CA2497798A1 (en)
WO (1) WO2004032622A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1720990A4 (en) 2004-02-27 2008-04-30 Dow Global Technologies Inc High efficiency peptide production in plant cells
WO2005108564A2 (en) * 2004-03-25 2005-11-17 Large Scale Biology Corporation Production of peptides in plants as viral coat protein fusion
EP1831372A2 (en) * 2004-12-30 2007-09-12 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
WO2017217460A1 (en) * 2016-06-15 2017-12-21 出光興産株式会社 Fusion protein containing at least two proteins linked to each other through peptide linker
CN111351929B (en) * 2020-01-15 2022-08-16 南京农业大学 Monoclonal antibody-based rapid detection test strip for cucumber green mottle mosaic virus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977438A (en) * 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
WO1991015587A1 (en) * 1990-04-06 1991-10-17 Commonwealth Scientific And Industrial Research Organisation Self-polymerising expression system based on modified potyvirus coat proteins
GB9108386D0 (en) 1991-04-19 1991-06-05 Agricultural Genetics Co Modified plant viruses as vectors
US5667782A (en) * 1992-07-16 1997-09-16 Oxford University Multiple particulate antigen delivery system
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
US5795754A (en) * 1995-07-19 1998-08-18 Merck & Co., Inc. Synthetic HPV11 virus-like particles
EP1123114B1 (en) * 1998-10-21 2005-12-28 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Virus-like particles for the induction of autoantibodies
WO2000039151A1 (en) * 1998-12-23 2000-07-06 Merck & Co., Inc. Neutralizing assay using human papillomavirus virus-like particles
US20030005410A1 (en) * 1999-06-02 2003-01-02 American Management Systems, Inc. Of Fairfax, Va. Xml parser for cobol
US6730306B1 (en) * 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
DK1450856T3 (en) * 2001-09-14 2010-05-31 Cytos Biotechnology Ag Packaging of Immunostimulatory CpG in Virus-Like Particles, Method and Use

Also Published As

Publication number Publication date
WO2004032622A2 (en) 2004-04-22
CA2497798A1 (en) 2004-04-22
EP1549140A2 (en) 2005-07-06
AU2003296902A1 (en) 2004-05-04
EP1549140A4 (en) 2009-04-29
WO2004032622A3 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
WO2001091536A3 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
WO2005055957A3 (en) Influenza immunogen and vaccine
JP2012501959A5 (en)
ATE417097T1 (en) RECOMBINANT RESPIRATORY SYNZYTIAL VIRUS EXPRESSION SYSTEM AND VACCINES
NL300324I1 (en) Papillomavirus-like particles, fusion proteins as well as method
JP2013241442A5 (en)
CA2193210A1 (en) Method of inducing an immune response with a live venezuelan equine encephalitis virus expressing a heterologous immunogen
ATE120234T1 (en) HIV-3 RETROVIRUS AND ITS USE.
WO2004001051A3 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
ATE516345T1 (en) IBDV (INFECTIOUS BURSAL DISEASE VIRUS) DERIVED CHIMERA EMPTY VIRUS-LIKE PARTICLES, METHOD FOR PREPARATION THEREOF AND APPLICATIONS
WO2004004761A3 (en) Adjuvant viral particle
WO2004032622A8 (en) Production of peptides in plants as viral coat protein fusions
WO2005108564A3 (en) Production of peptides in plants as viral coat protein fusion
FI885296A (en) RECOMBINANT HIV-2 POLYPEPTIDES.
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
WO2006112929A3 (en) The hiv gp-41-membrane proximal region arrayed on hepatitis b surface antigen particles as novel antigens
DK1334197T3 (en) Yeast-derived vaccine against IPNV
WO2001049712A3 (en) Vaccine against isav (infectious salmon anaemia virus)
MX2010010025A (en) Fusion protein that directs vaccine antigens to antigen-presenting cells, and applications thereof.
WO2002088339A3 (en) Bursal disease virus-like particles
PT871738E (en) RECOMBINANT VIRAL PARTICLES AND VACCINE AND ANTITUMAL APPLICATIONS
WO2001042299A3 (en) Hepatitis virus sentinel virus i (svi)
WO2002044323A3 (en) Vectors for expressing heterologous peptides at the amino-terminus of potyvirus coat protein, methods for use thereof, plants infected with same and methods of vaccination using same
WO2002069691A3 (en) Immunogenic hiv peptides for use as reagents and vaccines
JP2003514518A5 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2497798

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005/01807

Country of ref document: ZA

Ref document number: 200501807

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003296902

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003808079

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003808079

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP